Genmab (GMAB) is maintaining its 2025 financial guidance published on February 12, 2025.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Genmab Executes Share Buy-back Transactions in Early May 2025
- Genmab to Submit sBLA for Epcoritamab Combination in Follicular Lymphoma
- Genmab Continues Share Buy-back Program in April 2025
- Genmab price target lowered to DKK 1,990 from DKK 2,970 at HSBC
- Genmab’s Strong Market Position and Growth Potential Justifies Buy Rating
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue